Drug intelligence / Profile preview

SED80

Development stage: Preclinical
Lead developer: iDrop
Modality: Small Molecules

Overview

SED80 is a drug under development for the treatment of inflammation and pain associated with cataract surgery. The specific active ingredient, mechanism of action, molecular modality, and pharmacological class for SED80 are not disclosed in available public sources. The drug is being developed as an endocrine specialty medication, but details on pharmacodynamics, indications beyond ophthalmic use, or chemical composition are not available.

Brand names: SED80SED-80SED 80
Other names: SED80SED-80SED 80

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SED80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SED80.

Explore the full profile